<DOC>
	<DOCNO>NCT01005238</DOCNO>
	<brief_summary>The aim randomize clinical study show non-inferiority change anti-viral therapy telbivudine lamivudine patient achieve undetectable viral load week 24 telbivudine therapy compare continuous treatment telbivudine respect viral breakthrough rate week 108 primary clinical outcome .</brief_summary>
	<brief_title>Telbivudine Versus Lamivudine Maintenance Therapy Patients With Chronic Hepatitis B Negative HBV Viral Load After 6 Month Treatment With Telbivudine</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Male female patient , &gt; 18 ( complete 18th birthday ) . There upper limit age Documented HBeAg negative CHB HBsAg positive &gt; 6 month HBV DNA &gt; 2000 IU/mL Patient willing able comply study drug regimen study requirement . Written inform consent Antiviral HBV treatment naïve previous treatment interferonalpha pegylated interferonalpha stop least 1 month prior screen Decompensated liver cirrhosis accord judgment local investigator Hepatocellular carcinoma History laboratory sign coinfection HIV HCV , HDV Previous treatment antiviral drug ( previous treatment interferonα pegylated interferonα exclusion criterion , stop one month screen ) History hypersensitivity study drug drug similar chemical structure excipients Any medical condition require frequent prolong use systemic corticosteroid ( inhale , topic intraarticular corticosteroid allow ) Any medical condition require chronic prolong use potentially hepatotoxic drug nephrotoxic drug . Current abuse alcohol illicit drug . Use investigational drug time randomization , within 30 day 5 halflives enrollment , whichever longer . Any concurrent medical social condition , opinion investigator , likely preclude compliance schedule evaluation protocol , likely confound efficacy safety observation study . Any following laboratory value Screening : Hemoglobin ( HGB ) &lt; 11 g/dL men &lt; 10 g/dL woman Total WBC &lt; 3000/mm3 Absolute neutrophil count ( ANC ) &lt; 1,500.mm3 Platelet count &lt; 50'000/mm3 Serum amylase lipase ≥ 1.5 x ULN Serum albumin &lt; 3 g/dL Total bilirubin &gt; 51 μmol/L ( &gt; 3.0 mg/dL ) Estimated calculated serum creatinine clearance &lt; 50 mL/min use CockcroftGault method use actual ideal body weight whichever less ( Cockcroft Gault 1976 ) AFP ( alphafetoprotein ) &gt; 100 ng/mL ALT &gt; 10x ULN Women pregnant breastfeeding . Women childbearing potential must negative serum betahuman chorionic gonadotropin ( βHCG ) Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>